Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Hanmi Pharm (128940 KS): Flagship Drugs Boost 3Q25 Result Amid Obesity Pipeline Progress

Hanmi Pharm (128940 KS): Corporate Value Enhancement Plan Targets W5 Trillion Revenue by 2033

OCI Or No OCI, Hanmi Pharm (128940 KS) Will Continue to Roar on Strong Base Business and Pipeline

Hanmi Pharm (128940 KS): Export Drives 1Q25 Performance; China Business Is Recovering

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hanmi-pharm-co-ltd" target="_blank" data-smartkarma-citation="entities:12476:1" rel="noopener">Hanmi Pharm (128940 KS)</a> recorded 6% YoY revenue growth in domestic business in 2Q25, on continued growth of Rosuzet and stable revenue from Amosartan and Esomezol family of drugs.</li>
<li>The company has launched two new drugs in 2Q25. The company has co-launched Prolia biosimilar in Korea. Next-generation low dose triple antihypertensive, Amoprel has been launched in August.</li>
<li>Hanmi Pharm is advancing HM17321, a first-in-class obesity therapy, into global Phase 1 trials. With the leadership dispute overhang removed, Hanmi Pharm seems to be on the path of revival.</li>
</ul>



Hanmi Pharm (128940 KS) recorded 6% YoY revenue growth in domestic business in 2Q25, on continued growth of Rosuzet and stable revenue from Amosartan and Esomezol family of drugs.
The company has launched two new drugs in 2Q25. The company has co-launched Prolia biosimilar in Korea. Next-generation low dose triple antihypertensive, Amoprel has been launched in August.
Hanmi Pharm is advancing HM17321, a first-in-class obesity therapy, into global Phase 1 trials. With the leadership dispute overhang removed, Hanmi Pharm seems to be on the path of revival.


Hanmi Pharm (128940 KS): Domestic Business Fuels 2Q Result; New Launches to Drive Near-Term Growth